Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps.
Standard
Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps. / Hautmann, S; Huland, E; Wullbrand, A; Friedrich, Martin; Huland, H.
In: ANTICANCER RES, Vol. 20, No. 6, 6, 2000, p. 4495-4498.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps.
AU - Hautmann, S
AU - Huland, E
AU - Wullbrand, A
AU - Friedrich, Martin
AU - Huland, H
PY - 2000
Y1 - 2000
N2 - BACKGROUND: We studied the influence of interleukin-2 (IL-2) therapy on tumor growth and prevention of metastasis in metastatic, hormone-refractory prostatic carcinoma (PCa) in an animal model orthotopically (ortho) and subcutaneously (s.c.). MATERIALS AND METHODS: 75 juvenile male Copenhagen rats were divided into five groups of 15 rats each. MatLyLu-PCa (MLL) was implanted ortho (n = 30) in 2 groups or s.c. (n = 30) in 2 groups and were treated locally at the tumor site with micro-osmotic pumps. The rats in 2 groups received IL-2 pumps with 36 x 10(6) IU of IL-2 and the rats in 2 other groups were treated with pumps delivering albumin only as a control. The rats in the last group received ortho MLL and s.c. IL-2 (n = 15). Survival time was then monitored. RESULTS: Prostatic tumor was found in all ortho animals. Additionally lymphogenic and pulmonary metastasis was found in all animals. The orthotopic and s.c. IL-2-treated groups showed a statistically significantly increased survival compared with the orthotopic and s.c. albumin-treated groups. When treating the ortho MLL with s.c. IL-2 there was still a statistically significant longer survival than in the control groups. CONCLUSION: IL-2 therapy significantly reduces tumor growth of rats with metastatic, hormone-refractory prostatic cancer MatLyLu.
AB - BACKGROUND: We studied the influence of interleukin-2 (IL-2) therapy on tumor growth and prevention of metastasis in metastatic, hormone-refractory prostatic carcinoma (PCa) in an animal model orthotopically (ortho) and subcutaneously (s.c.). MATERIALS AND METHODS: 75 juvenile male Copenhagen rats were divided into five groups of 15 rats each. MatLyLu-PCa (MLL) was implanted ortho (n = 30) in 2 groups or s.c. (n = 30) in 2 groups and were treated locally at the tumor site with micro-osmotic pumps. The rats in 2 groups received IL-2 pumps with 36 x 10(6) IU of IL-2 and the rats in 2 other groups were treated with pumps delivering albumin only as a control. The rats in the last group received ortho MLL and s.c. IL-2 (n = 15). Survival time was then monitored. RESULTS: Prostatic tumor was found in all ortho animals. Additionally lymphogenic and pulmonary metastasis was found in all animals. The orthotopic and s.c. IL-2-treated groups showed a statistically significantly increased survival compared with the orthotopic and s.c. albumin-treated groups. When treating the ortho MLL with s.c. IL-2 there was still a statistically significant longer survival than in the control groups. CONCLUSION: IL-2 therapy significantly reduces tumor growth of rats with metastatic, hormone-refractory prostatic cancer MatLyLu.
M3 - SCORING: Zeitschriftenaufsatz
VL - 20
SP - 4495
EP - 4498
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 6
M1 - 6
ER -
